ERBB2 and breast cancer: We identified 117 non‐synonymous ERBB2 mutations in 103 patients (3.2%), higher than the previously reported incidence rates of 1.6%‐2.4% (Bose et al, 2013; Wen et al, 2015; Ross et al, 2016), but lower than in metastatic BC where rates as high as ~ 7% have been reported (Cocco et al, 2018).